Compare Cassava Sciences Inc (FLNA) vs Sibanye Stillwater Ltd (SBSW) Price & Performance

FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.

The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.

SBSW trades at $9.99, up 3.2% today, showing mixed technical signals with a bearish moving average trend but neutral oscillators. Fundamentally, the company demonstrates strong operational improvement with 2025 revenue reaching $129.68B and positive net cash flow of $1.13B, though it posted a net loss of $5.17B. Recent Q2 2026 earnings beat expectations with $1.34 EPS versus $1.26 expected, indicating potential turnaround momentum. Analyst consensus remains positive with a $14.25 price target representing 43% upside potential from current levels.

The stock presents a compelling value opportunity with attractive valuation multiples (P/E 8.12, P/S 0.7) and strong profitability metrics (ROE 34.37%), but faces execution risks from recent net losses and high debt levels. Key catalysts include continued operational improvements and commodity price support, while risks involve debt management and margin pressures. Institutional sentiment appears constructive with recent position increases by major funds.